Related Experiment Video
Updated: Aug 20, 2026
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
Secretomers as a new tool for the monitoring of CTL responses
Bastien Calmels1, Stephane Paul, Christelle Ziller
1Transgene S.A., Molecular Immunology Laboratory, Strasbourg, 67082, France. calmels@transgene.fr
Abstract:
Efforts to follow tumor-specific immune responses in patients are often thwarted by lack of knowledge of the appropriate tumor antigens and the CTL epitopes of those antigens. There is, therefore, a growing need for techniques to monitor tumor-specific immune responses in settings where tumor antigens, and antigenic epitopes, remain unidentified. Here we describe a novel system to follow tumor-specific CTL immune responses. A truncated, soluble murine class I MHC (H-2Db) molecule was fused with a rat IgG2a Fc, in order to allow secretion of the complex. Tumor-specific CTL could then be detected as a result of the complex fastening to specific T cell receptors (TCR). These constructs were inserted into the genome of a recombinant adenovirus vector. Infection of tumor cells with these adenovirus constructs results in the secretion of the complexes into the culture supernatant. These soluble divalent class I MHC molecules were used to detect and activate specific CTL populations.
Insights
This study introduces a new method to track tumor-specific immune responses by detecting cytotoxic T lymphocytes (CTLs) even when tumor antigens are unknown. The novel system uses engineered molecules to identify and activate these crucial immune cells.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Monitoring tumor-specific immune responses is challenging due to unidentified tumor antigens and T cell epitopes.
- A need exists for methods to track immune responses when antigens are unknown.
Purpose of the Study:
- To develop a novel system for detecting and activating tumor-specific cytotoxic T lymphocytes (CTLs) when antigens are not identified.
- To enable monitoring of anti-tumor immunity in diverse clinical settings.
Main Methods:
- A truncated, soluble murine class I MHC (H-2Db) molecule was fused with a rat IgG2a Fc fragment for secretion.
- This construct was incorporated into a recombinant adenovirus vector for expression in tumor cells.
- Secreted soluble MHC-Fc complexes were used to bind to T cell receptors (TCRs) on CTLs.
Main Results:
- The engineered adenovirus successfully produced and secreted soluble divalent MHC-Fc complexes.
- These complexes effectively detected specific CTL populations by binding to their TCRs.
- The soluble molecules demonstrated the ability to activate specific CTL populations.
Conclusions:
- The developed system provides a novel approach to detect and monitor tumor-specific CTL responses.
- This method is valuable for studying anti-tumor immunity, particularly when tumor antigens are unknown.
- The technology holds potential for advancing cancer immunotherapy research and patient monitoring.
